Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1463508

USP

Nifedipin

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridindicarbonsäure-dimethylester

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C17H18N2O6
CAS-Nummer:
21829-25-4
Molekulargewicht:
346.33
EG-Nummer:
244-598-3
MDL-Nummer:
MFCD00057326
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750558
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

nifedipine

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC

InChI

1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3

InChIKey

HYIMSNHJOBLJNT-UHFFFAOYSA-N

Angaben zum Gen

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Anwendung

Nifedipine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Nifedipine Capsules
  • Nifedipine Extended-Release Tablets

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

N0750000

Nifedipin, European Pharmacopoeia (EP) Reference Standard

N0750010

Nifedipin-Unreinheit A, European Pharmacopoeia (EP) Reference Standard

1463600

Nifedipinnitrophenylpyridin-Analogon, United States Pharmacopeia (USP) Reference Standard

N0750015

Nifedipin-Unreinheit B, European Pharmacopoeia (EP) Reference Standard

1463701

Nifedipinnitrosophenylpyridin-Analogon, United States Pharmacopeia (USP) Reference Standard

BP462

Nifedipin, British Pharmacopoeia (BP) Reference Standard

BP866

Dimethyl-2,6-dimethyl-4-(2-nitrosophenyl)-3,5-Pyridindicarboxylat, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

P D Henry et al.
The Journal of clinical investigation, 68(5), 1366-1369 (1981-11-01)
We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions
P D Henry
The American journal of cardiology, 46(6), 1047-1058 (1980-12-01)
Calcium antagonists (slow channel blocking agents) are a very heterogeneous group of agents with dissimilar structural, electrophysiologic and pharmacologic properties. Nifedipine is a potent, long-acting vasodilator that has proved highly efficacious in relieving anginal symptoms caused by coronary vasospasm. In
Stability studies on nifedipine tablets using thermogravimetry and differential scanning calorimetry.
Franco, P. I. B. M., E. C. Conceic?o, and M. I. G. Leles.
Journal of Thermal Analysis and Calorimetry, 93.2, 381-385 (2008)
Ryuichi Morishita et al.
Drugs, 66 Spec No 1, 31-33 (2008-01-19)
Useful drug therapy for inhibiting the extension of an aortic aneurysm or promoting its involution has not yet been established. Hypertension is a known risk factor for extension of an aortic aneurysm. However, on a cellular level it is believed
Norio Taira
Drugs, 66 Spec No 1, 1-3 (2008-01-19)
Nifedipine was synthesized by Bayer Germany in 1966 and considered for clinical use as a coronary vasodilator in patients with angina pectoris. Japanese investigators played a great part in the pre-clinical and clinical development of nifedipine. Professor Hashimoto demonstrated that
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.